RxDoctor Payments Data

April Davis, APRN

Psychiatric/Mental Health · Baton Rouge, LANPI 1689320871

Payments from drug & device makers

$4,218in general payments, 2019–2025

Across 205 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$533
  • Indivior Inc.$509
  • AbbVie$427
  • Alkermes, Inc.$413
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$318
  • plus $782 from 5 others

What the payments were for

  • Food & beverage$4,16999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,218 in reported general payments places this provider in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,662
Medicare patients
15
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$176,638
Invega SustennaPaliperidone Palmitate57$159,195
CaplytaLumateperone Tosylate12$22,736
Lurasidone Hcl48$12,126
Paliperidone ErPaliperidone30$4,095
Aripiprazole97$3,469
Ziprasidone Hcl48$2,762
Divalproex Sodium ErDivalproex Sodium62$2,576
Quetiapine Fumarate141$2,155
Buspirone Hcl99$1,745
Trazodone Hcl119$1,636
Risperidone114$1,546
Fluoxetine Hcl90$1,488
Oxcarbazepine36$1,416
Haloperidol Decanoate21$1,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$533$176,63821 claims
Johnson & JohnsonInvega Sustenna$157$159,19557 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$318$22,73612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →